Tech Center 1600 • Art Units: 1649 1675
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17809376 | EXPRESSION OF NEUROPEPTIDES | Non-Final OA | California Institute of Technology |
| 15893456 | USE OF GUT MICROBIOTA IN THE DIAGNOSIS AND THERAPEUTICS OF PARKINSON'S DISEASE | Non-Final OA | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 17111820 | PEPTIDIC LINKER WITH REDUCED POST-TRANSLATIONAL MODIFICATION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18359633 | Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) | Final Rejection | Revance Therapeutics, Inc. |
| 17234690 | BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT | Final Rejection | Revance Therapeutics, Inc. |
| 17127810 | MONOCLONAL ANTIBODY FUSIONS | Final Rejection | Quidel Corporation |
| 17569019 | METHOD OF PROVIDING DISEASE-SPECIFIC BINDING MOLECULES AND TARGETS | Non-Final OA | University of Zürich |
| 17676085 | Therapeutic Protein Formulations | Non-Final OA | Gloriana Therapeutics, Inc. |
| 16521298 | STEM CELL MICROPARTICLES AND miRNA | Non-Final OA | RENEURON LIMITED |
| 16564893 | DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Non-Final OA | Kadimastem Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy